Uric Acid Stones Clinical Trial
Official title:
Toxicity of Perirenal Fat in Overweight or Obese Subjects: A Pathophysiological Link Between Uric Acid Stones and Renal Ammonium Formation
Verified date | March 2018 |
Source | Centre Hospitalier Universitaire de Nice |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients who are overweight or obese, diabetic or not, share with those who are suffering
from uric stones the same way to remove abnormal acidity of the body in urine, ie a kidney
ammoniogenesis default. This results in an overly acidic urine pH which is directly
pathogenic in people predisposed to develop uric stones because the precipitation of urate
soluble uric acid is accelerated in acid medium.
Excess visceral fat, particularly perirenal, this defect may promote formation of renal
ammonium. Indeed, the perirenal fat is adjacent to the renal cortex and shares with it a
common arterial supply via the plexus Turner. Adipokines and fatty acids of the perirenal fat
are predisposed to gain the renal cortex, seat of the ammoniogenesis. In humans the
pathogenic role of the perirenal fat is demonstrated in chronic kidney disease and essential
hypertension. However, the amount of fat and perirenal that of intra-abdominal fat are
positively correlated.
Investigators hypothesis is that the perirenal fat also exert a pathogenic role in uric
because of anatomical links between kidney stones and greasy environment and because excess
fatty acids reaching the renal cortex decreases ammoniogenesis in an animal model metabolic
syndrome.
For the test, the investigators will compare the amount of fat and perirenal renal ability to
form ammonium in patients with uric or calcium lithiasis taking into account the amount of
intra-abdominal fat.
Status | Completed |
Enrollment | 20 |
Est. completion date | September 29, 2016 |
Est. primary completion date | June 24, 2016 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Urolithiasis Uric defined by more than 90% of uric acid anhydrous and / or dihydrate or calcium lithiasis defined by more than 90% mono calcium oxalate and / or dihydrate, and / or carbapatite and / or brushite; - Overweight and obesity defined by 25 <BMI <35 kg / m2 Exclusion Criteria: - staghorn lithiasis, stones struvite or cystine; - Primary hyperparathyroidism; - Hyperthyroidism; - Any form of calcium or uric lithiasis secondary; - Abnormal kidney structure (cysts, cortical thinning, kidney tumor); |
Country | Name | City | State |
---|---|---|---|
France | CHU de Nice | Nice |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Nice |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the perirenal fat thickness (left) | This is the perirenal fat thickness measured between the left posterior wall of the kidney and the posterior wall of the abdominal cavity on a TDM section in the plane of the left renal vein. | baseline | |
Secondary | the perirenal fat thickness (right) | the average thickness of perirenal fat measured to the right | baseline | |
Secondary | NH4 + / NAE | It is the ratio NH4 + / NAE measured over 24 hours of urine collected at day 7 of a standard diet; it determines from acid removed as ammonium whose production is regulated physiologically by the kidneys | at day 7 of a standard diet | |
Secondary | net acid urinary flow | This is the net acid urinary flow and report NH4 + / creat obtained when the urine pH became <5.5, in an acidic filler. | at day 7 of a standard diet and when urine pH became <5.5 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06335537 -
Impact of Sodium Bicarbonate on 24-hour Urine Parameters in Hypocitriuric and Uric Acid Stone Formers
|
Phase 1 | |
Recruiting |
NCT04621929 -
Obesity and Uric Acid Stones Study
|
Phase 3 | |
Recruiting |
NCT06118320 -
The Effective of Potassium Sodium Hydrogen Citrate in Treating Uric Acid Stones Using Gut Microbiota and Metabolomics.
|
||
Recruiting |
NCT04352153 -
Role of Uralyt-U in Patients With Hyperuricemia
|
N/A |